Colorectal Cancer

Navesh K. Sharma, DO, PhD, associate professor of Radiology, Division of Radiology and Oncology, Penn State Hershey Medical Center, section chief of Radiation Oncology, Penn State Health St. Joseph Cancer Center, discusses the results of the SIRFLOX study in patients with metastatic colorectal cancer (mCRC).

If an overall survival advantage is found for patients receiving first-line FOLFOX6 with or without bevacizumab plus Yttrium-90 resin microspheres for liver metastatic colorectal cancer.

Practitioners received insight into treating patients across the GI field during the GI cancers track at the 2016 Chemotherapy Foundation Symposium.

Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses how mutation status effects individualization of treatment in metastatic colorectal cancer (mCRC).

In patients with metastatic colorectal cancer (mCRC), the correlation between tumor location and improved survival varies based on stage of disease, according to a study.

Mutation discordance between primary and metastatic sites in colorectal cancer (CRC) may occur more often than previously understood, opening the door for potential new therapeutic approaches to treating the disease.

Advanced Colorectal Cancer with Marwan G. Fakih, MD

Advanced Colorectal Cancer with Marwan G. Fakih, MD

Mikhail Fedyanin, MD, medical oncologist, Russian Academy of Medical Sciences, Moscow, discusses some of the factors associated with discordance in mutation status in metastatic colorectal cancer during the 2016 ESMO Congress.

Advanced Colorectal Cancer with Michael Morse, MD

Advanced Colorectal Cancer with Michael Morse, MD

A genetic understanding of dMMR in rectal cancer could lead the way to precision medicine for these subgroups of patients

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses the need for better surrogate parameters for overall survival in colorectal cancer.